Sanofi: Diabetes Mellitus, Type 2 trials

The registry lists 186 Diabetes Mellitus, Type 2 studies with Sanofi as lead sponsor. 1 are open to participants now and 46 have results posted.

Phase 1 16Phase 2 8Phase 3 80Phase 4 75No phase 7(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• iGlarLixi CGM Study in Chinese T2D Individuals After OADsRecruitingNCT06671587Phase 4
• Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal ImpairmentTerminatedNCT05552859Phase 4Results posted
• iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)CompletedNCT05413369Phase 3Results posted
• Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusCompletedNCT05114590Phase 4Results posted
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With SulfonylureaTerminatedNCT03770728Phase 3Results posted
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)TerminatedNCT03713684Phase 3Results posted
• Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminTerminatedNCT03684642Phase 3Results posted
• Effect of Efpeglenatide on Cardiovascular OutcomesTerminatedNCT03496298Phase 3Results posted
• Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsTerminatedNCT03434119Phase 3Results posted
• Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin GlargineCompletedNCT03211858Phase 3Results posted
• A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes MellitusCompletedNCT02973321Phase 2Results posted
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedNCT02787551Phase 3Results posted
• Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistCompletedNCT02738151Phase 4Results posted
• A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)CompletedNCT02451137Phase 4Results posted
• Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic MedicationsCompletedNCT02320721Phase 3Results posted
• Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin GlargineCompletedNCT02294474Phase 3Results posted
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 DiabetesCompletedNCT02058160Phase 3Results posted
• Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMCompletedNCT02058147Phase 3Results posted
• Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic PatientsCompletedNCT01798706Phase 3Results posted
• Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsCompletedNCT01768559Phase 3Results posted
• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic TherapyCompletedNCT01676220Phase 3Results posted
• Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without MetforminCompletedNCT01596504Phase 2Results posted
• Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on MetforminCompletedNCT01517412Phase 3Results posted
• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic TherapyCompletedNCT01499095Phase 3Results posted
• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime InsulinCompletedNCT01499082Phase 3Results posted
• Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic PatientsCompletedNCT01476475Phase 2Results posted
• Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes MellitusCompletedNCT01226043Phase 4Results posted
• Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 DiabetesCompletedNCT01175473Phase 2Results posted
• Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by MetforminCompletedNCT01169779Phase 3Results posted
• Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents FailureCompletedNCT01117350Phase 4Results posted
• 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 YearsCompletedNCT00976937Phase 3Results posted
• 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin GlargineCompletedNCT00975286Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)CompletedNCT00905255Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)CompletedNCT00866658Phase 3Results posted
• Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension TrialCompletedNCT00851903Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of PioglitazoneCompletedNCT00763815Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00763451Phase 3Results posted
• Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive PatientsCompletedNCT00751114Phase 4Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal InsulinCompletedNCT00715624Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of SulfonylureaCompletedNCT00713830Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00712673Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedNCT00707031Phase 3Results posted
• GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in MonotherapyCompletedNCT00688701Phase 3Results posted
• Insulin Glargine "All to Target" TrialCompletedNCT00384085Phase 4Results posted
• Insulin Glulisine in Type 2 Diabetic PatientsCompletedNCT00360698Phase 4Results posted
• Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory ControlTerminatedNCT00283049Phase 4Results posted
• The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)CompletedNCT00069784Phase 3Results posted
• A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusCompletedNCT06716424Phase 4
• Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of AgeCompletedNCT06582056Not applicable
• A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in TaiwanCompletedNCT05684341Not applicable
• A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in IndiaCompletedNCT05628090
• A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 DiabetesCompletedNCT05607160
• A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension PeriodCompletedNCT05002933Phase 4
• Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic DrugsCompletedNCT04980027Phase 4
• Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03802487Phase 1
• Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinCompletedNCT03798080Phase 3
• Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)CompletedNCT03798054Phase 3
• Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveCompletedNCT03794336Phase 4
• A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted ConditionsCompletedNCT03776227Phase 1
• Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT03767543Phase 3
• Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaTerminatedNCT03761134Phase 3
• Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of InsulinCompletedNCT03760991Phase 4
• Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and ExerciseTerminatedNCT03760965Phase 3
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)CompletedNCT03529123Phase 3
• Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver DiseaseWithdrawnNCT03437720Phase 2
• A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension PeriodCompletedNCT03414736Phase 1
• A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideCompletedNCT03387657Phase 1
• A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese SubjectsCompletedNCT03376802Phase 1
• Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyCompletedNCT03359837Phase 4
• A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus PatientsCompletedNCT03350191Phase 1
• Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsCompletedNCT03310944Phase 1
• Sotagliflozin Bioequivalence StudyCompletedNCT03211195Phase 1
• Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin TreatmentCompletedNCT02967237Phase 4
• A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinCompletedNCT02967224Phase 4
• A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal InsulinCompletedNCT02967211Phase 4
• A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyCompletedNCT02954692Phase 4
• Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanCompletedNCT02941367Phase 4
• A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and MetoprololCompletedNCT02940379Phase 1
• Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic TherapyCompletedNCT02855684Phase 3
• Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and HypertensionCompletedNCT02842359Phase 4
• Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)CompletedNCT02836704Phase 4
• A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02803918Phase 1
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02752828Phase 3
• Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsCompletedNCT02752412Phase 3
• Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanCompletedNCT02749890Phase 3
• Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes MellitusCompletedNCT02713477Phase 1
• Treatment of Type 2 Diabetes With Long Acting Basal Insulin in JordanCompletedNCT02606357Phase 4
• Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using ToujeoCompletedNCT02585674Phase 3
• Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)CompletedNCT02545842Phase 4
• Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) PatientsCompletedNCT02411825Phase 1
• Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus PatientsCompletedNCT02401243Phase 3
• Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT02343926Phase 3
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic PatientsTerminatedNCT02274740Phase 2
• Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DMCompletedNCT02227212Phase 3
• TOFO Insulin Combination TrialCompletedNCT02201004Phase 4
• Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin GlargineCompletedNCT02200991Phase 4
• Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor TherapyCompletedNCT02027753Phase 4
• Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 DiabetesCompletedNCT01960179Phase 3
• Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 DiabetesCompletedNCT01940965Phase 3
• Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately ControlledCompletedNCT01699932Phase 3